Rifampicin-induced CYP3A4 activation in CTX patients cannot replace chenodeoxycholic acid treatment.
Szalat A, Gershkovich P, Ben-Ari A, Shaish A, Liberman Y, Boutboul E, Gotkine M, Hoffman A, Harats D, Leitersdorf E, Meiner V.
Szalat A, et al. Among authors: leitersdorf e.
Biochim Biophys Acta. 2007 Jul;1771(7):839-44. doi: 10.1016/j.bbalip.2007.04.012. Epub 2007 May 1.
Biochim Biophys Acta. 2007.
PMID: 17553741
Clinical Trial.